Safety, Tolerance, Pharmacokinetic and Antiviral Study of Amdoxovir in Combination With Zidovudine in Adults With HIV
Completed
RFS Pharma, LLC
Phase 1/Phase 2
2007-02-01
The purpose of this study is to determine the short term safety, tolerance, and antiviral
effect of zidovudine (AZT) and amdoxovir (AMDX, DAPD) in combination, and whether the dosage
for AZT can be reduced, potentially decreasing side effects, while maintaining antiviral
effects.
Study hypothesis: DADP in combination with AZT is safe and effective, and AZT dosing may be
reduced, resulting in lower levels of AZT-monophosphate associated with toxicity and
maintaining levels of AZT-triphosphate associated with efficacy.
Evaluation of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Africa (ANRS 12115 DAYANA)
Completed
Gilead Sciences
Phase 3
2008-07-01
The goal of this trial is to demonstrate that new treatments are as effective as a reference
triple-agent regimen in driving plasma viral load below the detection limit early during
treatment (16 weeks). These simplified treatments involve fewer tablets and intakes,
fixed-dose combinations, and also radically new strategies such as boosted protease inhibitor
and tenofovir.
Evaluation of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Africa (ANRS 12115 DAYANA)
Completed
Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
Phase 3
2008-07-01
The goal of this trial is to demonstrate that new treatments are as effective as a reference
triple-agent regimen in driving plasma viral load below the detection limit early during
treatment (16 weeks). These simplified treatments involve fewer tablets and intakes,
fixed-dose combinations, and also radically new strategies such as boosted protease inhibitor
and tenofovir.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
